ClinicalTrials.gg
WithdrawnNCT00323570Updated Jun 27, 2012

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

A Phase 3 interventional study of activated recombinant human factor VII in Acquired Bleeding Disorder and Trauma, sponsored by Novo Nordisk A/S. Withdrawn at 42 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-06-27.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma

Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

02

Conditions studied

  • Acquired Bleeding Disorder
  • Trauma

Browse trials for

03

In context

Wounds and Injuries

2,217 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.

Browse Wounds and Injuries studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)
06

What researchers measure

Primary outcomes

  1. Mortality and Morbidity

    Time frame: through day 30

Secondary outcomes

  1. All cause mortality

  2. Hospital-free days

  3. Number of transfusion units

  4. Days free of renal replacement therapy

  5. ICU-free days

  6. Days free of ventilator support

07

Study locations

42 sites
  • Novo Nordisk Clinical Trial Call Center
    Phoenix, Arizona 85008, United States
  • Novo Nordisk Clinical Trial Call Center
    Los Angeles, California 90033, United States
  • Novo Nordisk Clinical Trial Call Center
    Sacramento, California 95817, United States
  • Novo Nordisk Clinical Trial Call Center
    Colorado Springs, Colorado 80909, United States
  • Novo Nordisk Clinical Trial Call Center
    Washington, District of Columbia 20010-2975, United States
  • Novo Nordisk Clinical Trial Call Center
    Gainesville, Florida 32610, United States
  • Novo Nordisk Clinical Trial Call Center
    Jacksonville, Florida 32209, United States
  • Novo Nordisk Clinical Trial Call Center
    Miami, Florida 33136, United States
  • Novo Nordisk Clinical Trial Call Center
    Chicago, Illinois 60612, United States
  • Novo Nordisk Clinical Trial Call Center
    Maywood, Illinois 60153, United States
  • Novo Nordisk Clinical Trial Call Center
    Indianapolis, Indiana 46202, United States
  • Novo Nordisk Clinical Trial Call Center
    Louisville, Kentucky 40202, United States
  • Novo Nordisk Clinical Trial Call Center
    Portland, Maine 04102, United States
  • Novo Nordisk Clinical Trial Call Center
    Baltimore, Maryland 21201, United States
  • Novo Nordisk Clinical Trial Call Center
    Boston, Massachusetts 02118, United States
  • Novo Nordisk Clinical Trial Call Center
    Detroit, Michigan 48201, United States
  • Novo Nordisk Clinical Trial Call Center
    Springfield, Missouri 65804, United States
  • Novo Nordisk Clinical Trial Call Center
    St. Louis, Missouri 63110-0250, United States
  • Novo Nordisk Clinical Trial Call Center
    Las Vegas, Nevada 89102, United States
  • Novo Nordisk Clinical Trial Call Center
    Camden, New Jersey 08103, United States
  • Novo Nordisk Clinical Trial Call Center
    Bronx, New York 10461, United States
  • Novo Nordisk Clinical Trial Call Center
    Brooklyn, New York 11203, United States
  • Novo Nordisk Clinical Trial Call Center
    Greenville, North Carolina 27835-6028, United States
  • Novo Nordisk Clinical Trial Call Center
    Winston-Salem, North Carolina 27157, United States
  • Novo Nordisk Clinical Trial Call Center
    Akron, Ohio 44304, United States
  • Novo Nordisk Clinical Trial Call Center
    Cleveland, Ohio 44109, United States
  • Novo Nordisk Clinical Trial Call Center
    Columbus, Ohio 43214, United States
  • Novo Nordisk Clinical Trial Call Center
    Oklahoma City, Oklahoma 73104, United States
  • Novo Nordisk Clinical Trial Call Center
    Portland, Oregon 97239-3098, United States
  • Novo Nordisk Clinical Trial Call Center
    Allentown, Pennsylvania 18103, United States
  • Novo Nordisk Clinical Trial Call Center
    Philadelphia, Pennsylvania 19102, United States
  • Novo Nordisk Clinical Trial Call Center
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Clinical Trial Call Center
    Philadelphia, Pennsylvania 19140-5189, United States
  • Novo Nordisk Clinical Trial Call Center
    Pittsburgh, Pennsylvania 15213-2582, United States
  • Novo Nordisk Clinical Trial Call Center
    Providence, Rhode Island 02903, United States
  • Novo Nordisk Clinical Trial Call Center
    Memphis, Tennessee 38163, United States
  • Novo Nordisk Clinical Trial Call Center
    Nashville, Tennessee 37212, United States
  • Novo Nordisk Clinical Trial Call Center
    Fort Sam Houston, Texas 78234-6315, United States
  • Novo Nordisk Clinical Trial Call Center
    Lackland AFB, Texas 78236-5300, United States
  • Novo Nordisk Clinical Trial Call Center
    San Antonio, Texas 78229-3900, United States
  • Novo Nordisk Clinical Trial Call Center
    Salt Lake City, Utah 84143, United States
  • Novo Nordisk Clinical Trial Call Center
    Madison, Wisconsin 53792, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2006
First posted
May 9, 2006
Start
May 2006
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Last update
Jun 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00323570
Lead sponsor
Novo Nordisk A/S
First posted
May 9, 2006
Start date
May 2006
Primary completion
Jun 2007
Completion
Jun 2007
Last update
Jun 27, 2012

Study contacts

Bartholomew Tortella, MD
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion